Stakeholders React to FDA's Push for Quality, Integrity, and Uniformity
September 24th 2025The FDA draft guidance "Considerations for Complying with 21 CFR 211.110" raises points to consider regarding drug products made using advanced manufacturing, batch uniformity, drug product integrity, and how manufacturers can incorporate process models into control strategies.